The first nationally focused company to develop AND support a network of dermatology-based, SRT skin cancer treatment practices
SkinCure Oncology helps practices capitalize on new technology to treat the ever-increasing incidence of skin cancer, which is expanding with the aging U.S. population. The company was created in 2016 by the founders of Accelitech and Dermatologist/Mohs surgeon Dr. Daniel J. Ladd. Until recently the primary intervention for non-melanoma skin cancer treatment centered on surgical interventions, with Mohs micrographic surgery existing as the “gold standard.” However, a new non-surgical alternative now exists, and the numbers of Mohs surgeons are limited. The goal for SkinCure Oncology is to provide better access to this new non-surgical alternative for certain patients, including those with co-morbid conditions of blood thinner maintenance and diabetic concerns. Traditional therapies are not workable for these types of patients. Upon researching the problem, Accelitech and Dr. Ladd realized that there exists a genuine need for non-surgical alternatives and better access to care.